

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 August 2020 (13.08.2020)



(10) International Publication Number
WO 2020/163743 A8

(51) International Patent Classification:

A61P 27/16 (2006.01) *C12N 15/86* (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2020/017257

(22) International Filing Date:

07 February 2020 (07.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/802,890	08 February 2019 (08.02.2019)	US
62/928,279	30 October 2019 (30.10.2019)	US
62/965,770	24 January 2020 (24.01.2020)	US

(71) Applicants: **DECIBEL THERAPEUTICS, INC.**
[US/US]; 1325 Boylston Street, Suite 500, Boston, MA
02215 (US). **REGENERON PHARMACEUTICALS,**


INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown,
NY 10591 (US).

(72) Inventors: **BURNS, Joseph**; 1325 Boylston St, Suite 500,
Boston, MA 02215 (US). **ELLIS, Kathryn**; 1325 Boyl-
ston St, Suite 500, Boston, MA 02215 (US). **PALERMO,**
Adam; 1325 Boylston St, Suite 500, Boston, MA 02215
(US). **SCHWANDER, Martin**; 1325 Boylston St, Suite
500, Boston, MA 02215 (US). **WHITTON, Jonathon**;
1325 Boylston St, Suite 500, Boston, MA 02215 (US).
SABIN, Leah; c/o Regeneron Pharmaceuticals, Inc., 777
Old Saw Mill River Road, Tarrytown, NY 10591 (US).
KYRATSOUS, Christos; c/o Regeneron Pharmaceuticals,
Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591
(US). **DRUMMOND, Meghan**; c/o Regeneron Pharma-
ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown,
NY 10591 (US).

(74) Agent: **BELLIVEAU, Michael, J.**; Clark & Elbing LLP,
101 Federal Street 15th Floor, Boston, MA 02110 (US).

(54) Title: COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN
DUAL VECTOR SYSTEMS

FIG. 1A



(57) Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

10 December 2020 (10.12.2020)

(15) Information about Correction:

see Notice of 10 December 2020 (10.12.2020)